Verastem (NASDAQ:VSTM) inks an agreement with Sanofi (NASDAQ:SNY) granting the latter exclusive rights to develop and commercialize COPIKTRA (duvelisib) for all oncology indications in Russia and the Commonwealth of Independent States (CIS), Turkey, the Middle East and Africa.
Under the terms of the agreement, Verastem will receive $5M upfront, up to $42M in milestones and double-digit royalties on net sales.
VSTM is up 5% after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.